Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILs with Nivolumab, Relatlimab, and Ipilimumab in advanced ovarian cancer
NCT04611126Phase 2Terminated
- Start
- Apr 2021
- Primary completion
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of relatlimab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms). Primary endpoints: Number of Patients Excluded Due to Treatment Related Safety Issues, Number of Participants Experiencing Grade III or Worse Adverse Events and 1 more. Started Apr 2021; status: terminated.
02
Drugs
relatlimab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04611126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04611126.